Abstract Cardiac neuronal nitric oxide synthase (nNOS) is an important molecule that regulates intracellular Ca 2+ homeostasis and contractility of healthy and diseased hearts. Here, we examined the effects of nNOS on fatty acid (FA) regulation of left ventricular (LV) myocyte contraction in sham and angiotensin II (Ang II)-induced hypertensive (HTN) rats. Our results showed that palmitic acid (PA, 100 μM) increased the amplitudes of sarcomere shortening and intracellular ATP in sham but not in HTN despite oxygen consumption rate (OCR) was increased by PA in both groups. 
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Carnitine palmitoyltransferase-1 inhibitor, etomoxir (ETO), reduced OCR and ATP with PA in sham and HTN but prevented PA potentiation of sarcomere shortening only in sham. PA increased nNOS-derived NO only in HTN. ] i and reduced myofilament Ca 2+ sensitivity following nNOS inhibition. Myocardial FA oxidation ( 18 Ffluoro-6-thia-heptadecanoic acid, 18 F-FTHA) was comparable between groups, but nNOS inhibition increased it only in HTN. Collectively, PA increases myocyte contraction through stimulating [Ca 2+ ] i and mitochondrial activity in healthy hearts. PA-dependent cardiac inotropy was limited by nNOS in HTN, predominantly due to its modulatory effect on [Ca
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Introduction
Nitric oxide (NO) is an important regulator of myocardial contractility in healthy and diseased hearts [20, 27] . Research from our own group and that of others has shown that NO modulates Electronic supplementary material The online version of this article (doi:10.1007/s00424-017-1991-1) contains supplementary material, which is available to authorized users. myocardial inotropy, facilitates lusitropy, and is important in the maintenance of cardiac function under pathological stimuli [21, 32, 35] . Recent consensus is that neuronal nitric oxide synthase (nNOS) is the predominant isoform of NOS that regulates intracellular Ca 2+ handling, myofilament Ca 2+ sensitivity, and contractility in cardiac myocytes from healthy and hypertensive rats [31, 32] . In the myocytes from healthy heart, nNOS-derived NO attenuates basal contractility of cardiac myocytes by modulating the activities of L-type Ca 2+ channels (LTCC) in the plasma membrane to reduce the amplitude of [Ca 2+ ] i transient or promoting Ca 2+ decline by increasing phospholamban phosphorylation [26, 33] . Recently, we have shown that nNOS protein expression and activity are up-regulated in left ventricular (LV) myocytes from hypertensive rat hearts, whereas endothelial NOS (eNOS) protein expression is reduced [13] . nNOS facilitated myocardial lusitropy by reducing myofilament Ca 2+ sensitivity; myofilament Ca 2+ desensitization, in turn, increased Ca 2+ handling [13, 31] .
Fatty acid (FA)-dependent beta-oxidation is an important source of myocardial ATP in healthy heart. As such, FAs are the predominant metabolic substrates that play crucial roles in cardiac metabolism and contractile function [6, 18] . During disease progression, beta-oxidation is down-regulated and glycolysis becomes the the main means for energy (metabolic shift) for the preservation of the pumping function of the heart [18] . In the failing myocardium, both glucose-and FAdependent metabolism are limited, and energy deficiency becomes an important precursor for impaired myocardial contraction. Until recently, the effects of FA on cardiac contractility in healthy and hypertensive rat hearts remain undetermined. Furthermore, the roles of nNOS on cardiac contraction in the presence of FA and the underlying mechanisms in healthy and hypertensive rat hearts need to be explored.
Palmitic acid (PA) is one of the most common long-chain saturated FAs for myocardial energetics [19] . FA oxidation can be affected by nNOS in vivo and in vitro in healthy and hypertensive rat hearts. Accordingly, we analyzed nNOS regulation of myocyte contraction and Ca 2+ handling with and without PA in LV myocytes from sham and angiotensin II (Ang II)-induced hypertensive rats.
Materials & methods Animals
Hypertension (HTN) was induced by infusing Ang II subcutaneously in Sprague-Dawley rats using osmotic minipumps, and the rats were paired with a sham-operated group. Briefly, the rats (of 8 weeks, male) were anesthetized with isoflurane (2.5%), and osmotic minipumps (rats, Alzet model 2004) containing Ang II (200 μl, 6 mM, infusion rate 125 ng/min/kg) were implanted in the mid-scapular region for 4 weeks. The sham-operated animals underwent the same surgical procedure, except for no pump insertion. Blood pressures were measured every 3 days (from 2 days before the operation) for 4 weeks using non-invasive tail-cuff method (CODA, Torrington, CT, USA).
Blood pressure and LV myocyte dimensions in sham and HTN rats
Both systolic and diastolic blood pressures (SBP and DBP) were increased from 1 week following Ang II infusion (125 ng/min/kg) and continuously increased, and heart rate was progressively slower up to the period studied. At 4 weeks, SBP, DBP, and heart rate were significantly different between sham and HTN rats ( Table 1 ). The diastolic sarcomere length was decreased, but the width of LV myocytes was not affected in HTN rats (Table 1) . Membrane capacitance (C m ) of LV myocytes (in whole-cell patch clamp technique) was increased in HTN rats.
Isolation of left ventricular myocytes
LV myocytes were isolated enzymatically by Langendorff perfusion system as recently described [36] . Briefly, the rats were anesthetized with pentobarbital sodium (30 mg/kg, i.p.), and the hearts were extracted and rapidly mounted onto the Langendorff perfusion system. The isolated heart was perfused with nominal Ca 2+ -free Tyrode's solution for 10 min (in mM NaCl 135, KCl 5.4, MgCl 2 3.5, glucose 5, HEPES 5, Na 2 HPO 4 0.4, Taurine 20; pH titrated to 7.40 using NaOH), followed by a further 8 min with the same solution with enzymes added (collagenase type 2, 1 mg/ml, Worthington Biochemical Co.; protease, 0.1 mg/ml, bovine serum albumin (BSA) 1.67 mg/ ml; Ca 2+ 0.05 mM). LV free wall was isolated and placed in a separate flask containing fresh collagenase type 2-containing solution for 8 min (oxygenated and maintained at 37°C). Myocytes were harvested following a further 10-min digestion period, washed, and re-suspended in storage solution (in mM NaCl 120, KCl 5.4, MgSO 4 ] i required for half relaxation (EC 50 ) was analyzed to quantify the relative changes in the myofilament Ca 2+ sensitivity. Measurements from at least ten steady-state contractions were averaged for each intervention. All experiments were carried out at 36 ± 1°C and fieldstimulated at 2 Hz [36] .
Measurement of oxygen consumption rate (OCR) from LV myocytes OCR was measured using a fluorescence-based oxygen sensor (NeoFox, Ocean Optics) connected to a phase measurement system (Instech). The sensor was calibrated every week according to the manufacturer's instructions. Briefly, isolated LV myocytes (density 2 × 10 4 /ml) were suspended in normal Tyrode's solution and were placed in a sealed chamber (300 μl). We recorded oxygen level in the chamber over 30-min period (37°C) followed by 5-min recordings with carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 20 μM) to evaluate maximum OC of the myocytes in the chamber. Changes in the OCR relative to the maximal OC with PA with and without nNOS inhibitor were calculated over 30-min period in sham and in HTN rats.
NO production
NO production was detected indirectly by measuring nitrite content in LV myocytes using NO assay kit (Sigma, Griess Reagent System). Briefly, LV myocytes were homogenized in HEPES buffer solution (in mM NaCl 141.4, KCl 4, NaH 2 PO 4 0.33, MgCl 2 1, HEPES 10, glucose 5.5, CaCl 2 1.8, mannitol 14.5, mixtures of phosphatase inhibitors and protease inhibitors; pH titrated to 7.40 using NaOH). After assaying the protein content with Bradford protocol, 50 μl of the supernatant of lysates was added to the wells and mixed with 50 μl of sulfanilamide solution and incubated for 5-10 min at room temperature in the dark. The same volume of naphthylethylenediamine dihydrochloride (NED, Sigma) solution was added to the wells and incubated for another 5-10 min at room temperature, protected from light. Absorbance of the mixture was measured with a microplate plate reader (at 540 nm, PowerWave™ XS Microplate Spectrophotometer, BioTek Instruments, USA). Sodium nitrite (Sigma) was used as a standard.
L-type Ca
2+ current recording LV myocytes were transferred to the mounting chamber on the stage of an inverted microscope (Nikon) and perfused continuously with Tyrode's solution containing (in mM NaCl 141.4, KCl 4, ) was recorded in the whole-cell configuration using an Axopatch 200A amplifier (Axon Instruments). I Ca was elicited by 200 ms step depolarization from a holding potential of −40 mV to test potentials ranging from −60 to +40 mV. Steady-state I Ca was assessed during a step to 0 mV at a stimulation frequency of 0.1 Hz. Membrane capacitance (C m ) was measured by applying a −10 mV hyperpolarizing ramp pulse immediately followed by a 10 mV depolarizing ramp of the same duration (100 ms) using the method by Golowasch et al. [10] . The range of membrane capacitance was also monitored directly from the window of Clampex 10.4. Recorded I Ca were normalized to C m and expressed as I Ca density (in pA/pF). Intracellular pipette solution contains (in mM CsOH 110, TEA-Cl 20, NaCl 10, HEPES 10, MgCl 2 1, MgATP 5, EGTA 10, Aspartate 110; pH titrated to 7.20 using CsOH, osmolarity 308 mOsm). Ca 2+ influx via LTCC was compared by calculating the integral of I Ca . The average of I Ca integrals at 0 mV with PA was compared between sham and HTN rats. Data were analyzed in Clampfit 10.
PET/CT image acquisition and analysis of FA oxidation in vivo

18
F-fluoro-6-thia-heptadecanoidc acid ( 18 F-FTHA) was synthesized from benzyl-14-(R,S)-tosyloxy-6-thiaheptadecanoate. Three sham and Ang II-induced HTN rats (12 weeks) were involved in the PET imaging study using radiotracer 18 F-FTHA in a dedicated small animal PET/CT scanner (eXplore Vista CT, GE Healthcare). Following water and food fasting for 6 h before PET/ CT scanning, the rats were anesthetized with 2% isoflurane and 2 l/min oxygen and were placed on the scanning bed in prone position and centered the heart in the field of view (FOV). 18 F-FTHA (5.0 ± 1.8 MBq) was administered via tail vein as a 0.5-ml bolus. In the small animal PET/CT system, static PET image acquisition began 40 min after the tracer injection for 5 min. A CT scan was acquired for image co-registration after the PET acquisition. On separate days, PET/CT acquisitions with the same protocol were performed 10 min after admission of NOS inhibitors i.v. SMTC (1 mg/kg) or L-NAME (5 mg/kg). Twodimensional ordered-subset expectation maximum (OSEM) algorithm was applied to PET image reconstruction. The reconstructed PET images were analyzed by a software package, AMIDE (ver. 1.0.4, Stanford University, Palo Alto, CA). After drawing a spherical volume-of-interest (VOI) covering the entire heart, LV myocardium (0.55 cm 3 -sized) of highest uptake was segmented in the VOI, in which mean uptake value of 18 F-FTHA was measured. The liver was chosen as a reference organ to calculate myocardium-to-liver ratio (MLR), for which mean uptake value of the liver was measured from a spherical VOI (0.57 cm 3 -sized) [11, 22] .
ATP production
Intracellular ATP level was determined using luminescence measurement of LV myocytes (ATP Bioluminescent Assay Kit, Sigma-Aldrich, Saint Louis, MO, USA). Briefly, LV myocytes were incubated in HEPES buffer solution (in mM NaCl 141.4, KCl 4, NaH 2 PO 4 0.33, MgCl 2 1, HEPES 10, glucose 5.5, CaCl 2 1.8, mannitol 14.5, pH 7.4 NaOH). Cells (1 × 10 5 /ml) were added to 200 μl of mammalian cell lysis solution (Tris-acetate buffer and 10% trichloroacetic acid as lysis buffer) and vortex the cell suspension tube for 10 min. Supernatant (100 μl) was added to 96-well white microplate, and ATP assay mix solution was added to the wells in the dark adapt stand at room temperature for 3 min. We then took an aliquot of the ATP standard solution and prepared a dilution series in Tris-acetate buffer from a concentration of 2 × 10 −4 M down to blank.
Chemicals
Angiotensin II (Ang II, 6 mM) was used to induce hypertension. Tiron (1 mM, Sigma) scavenges superoxide. S-methyl-Lthiocitrulline acetate salt (SMTC, 100 nM, Sigma) and Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME, 1 mM, Sigma) were used to target NOS activity. Sodium nitroferricyanide (III) dihydrate (SNP, 10 μM, Sigma) is an exogenous NO donor. Palmitic acid (PA, 100 μM, Sigma) was used as the substrate for the effect of FA. Etomoxir sodium salt hydrate (ETO, 100 μM, Sigma or 10 μM, Cayman) was used to inhibit the activity of CPT-1 (carnitine palmitoyltransferase-1). Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 20 μM, Sigma) was used to evaluate maximum oxygen consumption. 
Statistics
Data are expressed as means ± SEM or as relative to control (100%), and n indicates the number of cells used. For all comparisons, cells were obtained from a minimum of three hearts per treatment group per protocol. Data were analyzed using Student's t tests or ANOVA with multiple comparisons with Bonferroni correction. A value of p < 0.05 was considered to be statistically significant.
Results
PA increased LV myocyte contraction in sham but not in HTN rats
The effects of FA on contraction in isolated LV myocytes were examined in sham and in HTN rats. As shown in Fig. 1a , c, PA (100 μM) significantly increased sarcomere shortening in LV myocytes from sham rats (p < 0.0001, control vs. PA, n = 13). In contrast, the positive inotropic effect of PA was absent in HTN rats (p = 0.1, control vs. PA, n = 12). Pre-treatment of LV myocytes with an inhibitor of carnitine palmitoyltransferase-1 (CPT-1), ETO (10 μM, 30 min-1 h), abolished PA enhancement of myocyte contraction in sham rats (p = 0.37, control vs. PA with ETO, n = 5, Fig. 1d, f) Fig. 1e, f) .
Sustained pressure overload in hypertension is able to increase reactive oxygen species (ROS) and induce oxidative stress in the myocardium [3] . In addition, FAs have been implicated in the myocardial oxidative stress and modulate myocyte contractility in murine heart [8] . To investigate whether increased ROS in HTN rats may have prevented PA regulation of myocyte contraction, the effect of PA on LV myocyte was re-evaluated after incubation with a potent ROS scavenger, tiron (1 mM). Tiron pre-incubation did not affect myocyte contraction with PA in sham (p < 0.0001, Tiron vs. Tiron + PA, n = 8, Supplementary  Fig. 1 ) or in HTN rats (p = 0.24, Tiron vs. Tiron + PA, n = 7, Supplementary Fig. 1 ), excluding the role of ROS in preventing PA-induced myocyte contraction in HTN rats.
We performed experiments to observe whether PA affects mitochondrial activity (oxygen consumption rate, OCR) in LV myocytes from sham and HTN rats. As shown in Fig. 2a, b, PA increased basal OCR in both groups (p = 0.004 and p = 0.004, n = 10 and n = 9, respectively). Pre-treatment of LV myocytes with CPT-1 inhibitor, etomoxir (ETO, 10 μM, 30 min-1 h), prevented PA-induced increases of OCR in sham (p = 0.045, ETO vs. ETO + PA, n = 6 and n = 9) and in HTN (p = 0.01, ETO vs. ETO + PA, n = 5 and n = 11). Similarly, in vitro analysis of ATP level in LV myocytes showed that PA increased intracellular ATP and ETO prevented the effect in sham (p = 0.024, control vs. PA, n = 4; p = 0.0162, PA vs. ETO + PA, n = 4, Fig. 2c ). In HTN, PA did not increase intracellular ATP; however, ETO slightly but significantly reduced intracellular ATP level in the presence of PA (p = 0.209, control vs. PA, n = 4; p = 0.048, PA vs. ETO + PA, n = 4, Fig. 2d ).
PA increased nNOS-derived NO in HTN rats, which in turn, prevents PA stimulation of myocyte contraction
We aimed to identify PA regulation of nNOS activity in LV myocytes from sham and HTN rats. As shown in Fig. 3a , NO production (relative to control) was slightly but significantly reduced by PA in sham (p = 0.03, control vs. PA, n = 6). nNOS inhibition with SMTC did not affect PA modulation of NO production (p = 0.09, PA vs. PA + SMTC, n = 6, Fig. 3a) . In contrast, NO production was increased by PA in Fig. 3b ), suggesting the role of nNOS. Figure 3c showed that inhibition of nNOS with SMTC did not affect PA-induced OCR increase in sham (p = 0.02, SMTC vs. SMTC + PA, n = 8 and n = 10). In HTN, SMTC abolished PA-induced increase in OCR (p = 0.19, SMTC vs. SMTC + PA, n = 7 and n = 6). These results suggest that PA-dependent mitochondrial activity is increased in both sham and HTN rats, but this effect is attenuated with nNOS inhibition only in HTN rats.
Intriguingly, sarcomere shortening of LV myocyte was increased by PA following nNOS inhibition in HTN (SMTC, 100 nM, 30 min-1 h; p = 0.0005, SMTC vs. PA + SMTC, n = 10, Fig. 3f, g ). In contrast, nNOS inhibition exerted no effect on PA-dependent myocyte contraction in sham (p < 0.0001, SMTC vs. PA + SMTC, n = 15, Fig. 3e, g ). There is no difference in sarcomere shortening with PA between the two groups following nNOS inhibition (p = 0.1, SMTC + PA). These results suggest that nNOS is important in restricting PA enhancement of myocyte contraction in HTN rats.
Next, we examined FA metabolism and the response to nNOS and NOS inhibition by quantifying 18 F-FTHA uptake in vivo with PET/CT scanning in LV myocardium from sham and HTN rats. As shown in Supplementary  Fig. 2, myocardial 18 F-FTHA uptake was not different between the two groups at basal (p = 0.2382, sham control vs. HTN control, n = 3 each group). Inhibition of nNOS with SMTC did not affect 18 F-FTHA uptake in sham (p = 0.187, control vs. SMTC), but it was increased in HTN (p = 0.0284, control vs. SMTC). Subsequent infusion of L-NAME increased 18 F-FTHA uptake in sham (p = 0.0095, control vs. L-NAME, n = 3) and in HTN (p = 0.0397, control vs. L-NAME, n = 3). These results indicate that basal FA uptake is not different between sham and HTN; nNOS modulates myocardial FA uptake in HTN.
nNOS modulation of Ca 2+ handling prevents the inotropic effect of PA in HTN rats Next, we evaluated PA regulation of the key parameters of excitation-contraction coupling and the responses of these parameters to nNOS inhibition in sham and HTN rats.
Peak I Ca-L at 0 mV was reduced by PA in sham, but inactivation of LTCC was slower ( Supplementary Fig. 3) ; as a result, total Ca 2+ influx through LTCC (I Ca-L integral, I-LTCC ) was not changed by PA in sham (p = 0.4, n = 11, at 0 mV, Supplementary Fig. 4) . Inhibition of nNOS with SMTC increased peak I Ca-L with and without PA (p = 0.06, control vs. SMTC and p = 0.01, PA vs. SMTC + PA, n = 11 & 7) and slowed inactivation kinetics further (Supplementary Fig. 3 ). Accordingly, I-LTCC was increased after nNOS inhibition with and without PA in sham rats (p = 0.001 and p = 0.003, n = 11 and n = 7, respectively, Supplementary Fig. 4) .
In HTN, PA significantly reduced peak I Ca-L and slowed inactivation kinetics of LTCC (Supplementary Fig. 3 ) and I-LTCC at 0 mV was reduced (p = 0.0007, n = 8, Supplementary  Fig. 4) . Inhibition of nNOS with SMTC significantly increased peak I Ca-L at 0 mV and slowed tau further ( Supplementary Fig. 3 ). Consequently, I-LTCC was significantly increased following nNOS inhibition with PA in HTN rats (p = 0.001, PA vs. SMTC + PA, n = 8, at 0 mV, Supplementary  Fig. 4) .
Next, we detected the changes in [Ca 2+ ] i following PA supplementation with and without nNOS inhibition in sham and HTN rats. As shown in Fig. 4 ] i , p = 0.03, n = 11), but the effects were absent in HTN (systolic [Ca 2+ ] i , p = 0.13, n = 13; diastolic [Ca 2+ ] i , p = 0.31, n = 13). Inhibition of nNOS with SMTC significantly increased the amplitude of basal [Ca 2+ ] i in sham (p = 0.04, Fig. 4a-d) and PA no longer increased the peak amplitude of [Ca 2+ ] i in the presence of SMTC in sham (p = 0.3, n = 11, Fig. 4a-d) .
In contrast, SMTC pre-treatment significantly reduced the amplitude of basal [Ca 2+ ] i in HTN (p = 0.043, n = 13 & 9, Fig. 4b, e) . In addition, PA significantly increased [Ca 2+ ] i in the presence of SMTC (p = 0.009, SMTC vs. SMTC + PA, n = 9, Fig. 4b, e) ] i with PA before and after nNOS inhibition in sham and HTN rats.
As shown in Fig. 5a, c 
Discussion
Our present study demonstrates that PA increased mitochondrial activity in LV myocytes from sham and hypertensive rat hearts (via beta-oxidation) but it failed to increase myocyte contraction in the hypertensive group, contrary to that in the sham. Further analysis showed that PA increased nNOSderived NO in LV myocytes from hypertensive rats and NO mediated PA-dependent increase in mitochondrial activity. Nevertheless ] i . As shown in schematic diagram in Fig. 7 , our results demonstrate that PA is an active regulator of myocyte contraction through altering intracellular Ca 2+ handling in LV myocytes from both healthy and hypertensive rat hearts. nNOS in HTN restricts PA regulation of myocyte contractility by controlling [Ca 2+ ] i handling alongside its regulation of mitochondrial activity and myofilament property.
FAs are the predominant metabolic substrates to cardiac metabolism, and activation of β-oxidation in the mitochondria with FA supplementation produces more energy in the myocardium for its contractile function under normal conditions. Our results clearly showed that PA increased myocyte contraction, mitochondrial activity (OCR), and ATP production from healthy hearts and that the responses were blocked by CTP-1 inhibitor (ETO), supporting the role of β-oxidation and FA metabolism. In addition, convincing evidence showed that PA increased myocyte contraction by affecting [ [2, 9] . Furthermore, high concentrations of FAs (at mM range) have been implicated in the myocardial oxidative stress [8] . Intracellular ROS, in turn, either increase LV myocyte contraction by stimulating intracellular protein kinases (e.g., PKA) or by direct oxidation of proteins that are involved in myocyte contraction [34] or decrease myocyte contraction secondary to increased ROS in the myocardium from hypertensive models [35] . Pre-incubation of LV myocytes with tiron exerted no effect on myocyte responses to PA in sham or in HTN rats ( Supplementary Fig. 1 ), excluding the role of ROS in affecting PA-induced myocyte contraction in either group.
Previously, we have shown that nNOS protein expression and activity were increased in hypertensive rat LV myocytes which is responsible for myofilament Ca 2+ desensitization but enhanced [Ca 2+ ] i transient [13] Although cardiac metabolism and β-oxidation could be downregulated in hypertrophy and in heart failure myocardium, it may not be the case in the model of the current study. Our previous reports in echocardiography assessment clearly presented that myocardial contraction was not altered despite pressure overload in these rats [13] . It is possible that the metabolic status or substrate preference has not been modified in this early stage of hypertensive model yet. Indeed, in vivo examination of FA metabolism using PET/CT scanner showed that basal 18 F-FTHA uptake in the LV was not different between sham and HTN groups. Inhibition of nNOS with SMTC slightly but significantly increased FA metabolism in HTN without affecting it in sham. It is possible that greater contraction following myocardial nNOS inhibition may have increased energy demand via enhancing cardiac metabolism. On the other hand, systematic inhibition of nNOS may have activated Bsympathetic drive^and greater norepinephrine release from neural innervation [16] lead to enhanced myocyte contraction and FA metabolism in HTN rats. Subsequent inhibition of non-specific NOS with L-NAME significantly increased myocardial 18 F-FTHA uptake in both groups (supplementary Fig. 2) . NO has been implicated in modulating FA uptake and utilization in the mammalian myocardium from normal heart [4, 14, 15, 23, 24] . Furthermore, nNOS may affect myocardial function via regulating mitochondrial proteins, including complexes I, III, and IV, as shown in some studies [5, 29, 30] , reduce mitochondrial oxygen consumption, and affect cardiac metabolism. However, systematic inhibition of NOS in vivo may affect hemodynamics of the cardiovascular system (e.g., hypertension), resulting in NOS-independent effect on myocardial metabolism (e.g., increased energy demand). Notably, the FA metabolism was increased significantly more with L-NAME in sham rats compared to that in HTN rats ( Supplementary Fig. 2b ), possibly due to prerequisite pressure-overload and smaller margin for the myocardial responses in HTN rats. The effects of NO and the NOSs on myocardial FA metabolism and their roles in myocardial contractile function remain to be determined.
In conclusion, our results demonstrate novel evidence that although FA-dependent metabolism is an important regulator of myocardial contraction in healthy and hypertensive rats, nNOS-derived NO is up-regulated by FA in hypertension, which, in turn, modulates Ca 2+ handling process and controls myocardial response to FA. The functional relevance and the mechanistic insights into FA regulation of myocardial contractile function and its modification by nNOS are important in 
